What are your experiences with Polivy (polatuzumab vedotin-piiq) for treating lymphoma?
Polivy is now FDA-approved as part of a first-line treatment combination called Pola-R-CHP for previously untreated advanced diffuse large B-cell lymphoma (DLBCL). This treatment combines Polivy with rituximab, cyclophosphamide Show Full Answer
What are your experiences with Polivy (polatuzumab vedotin-piiq) for treating lymphoma?
Polivy is now FDA-approved as part of a first-line treatment combination called Pola-R-CHP for previously untreated advanced diffuse large B-cell lymphoma (DLBCL). This treatment combines Polivy with rituximab, cyclophosphamide, doxorubicin, and prednisone. Clinical trials have shown promising results with Pola-R-CHP, demonstrating:
• Lower risk of death
• Reduced chance of relapse
• Less disease progression
• Treatment typically involves 6 cycles
The success of treatment can vary based on several factors including:
• Age
• Overall health status
• DLBCL subtype
• Aggressiveness of the lymphoma
• Treatment tolerance
September 27, 2025